Sunshine Biopharma is preparing for an IND study of a new cancer drug that is expected to beat multidrug-resistant cancer - Benzinga

Sunshine Biopharma is preparing for an IND study of a new cancer drug that is expected to beat multidrug-resistant cancer – Benzinga


This post contains sponsored advertising content. This content is for informational purposes only and is not intended as investment advice.

Sunshine Biopharma Inc. SBFM announces steps to launch a new drug research (IND) anti-cancer drug study by a biopharmaceutical company focused on oncology – and recently announced that two of its newly designed mRNA molecules are effective in killing cancer cells grown in culture. The use of mRNA could prove to be a powerful ally in the fight against cancer.

The new compound is a new podophyllotoxin derivative, a promising new source of cancer-killing therapies, although it has so far shown little ability to target multidrug-resistant cancers.

Multi-resistant cancers no longer respond to many of the world’s leading cancer therapies, including chemotherapy. It hopes to change Sunshine’s Adva-27a drug candidate.

Topoisomerase II Inhibitors – A Promising Treatment That Kills Cancer?

Physicians sometimes use podophyllotoxin topoisomerase II inhibitors to treat difficult cancers. Podophyllotoxin is a naturally occurring toxin found in the plant Podophyllum (commonly known as mayapple or American mandrake). The perennial plant has been used for centuries by Native Americans to induce vomiting in the event of poisoning and killing parasites. It is also used as a topical antiviral to remove warts.

Recently, researchers have produced toxin derivatives that have shown promise in the treatment of cancer. By inhibiting topoisomerase II, which plays a key role in DNA replication, the toxin is able to effectively kill cancer cells.

The two derivatives available to physicians are etoposide and teniposide. Etoposide, sold under the brand name Toposar by Pfizer Inc. PFE, is currently used to treat small cell lung cancer, non – small cell lung cancer, leukemia, lymphoma and other severe cancers. The teniposide that is sold under the Vumon brand would Bristol-Myers Squibb Co. BMY, is used to treat many of the same types of cancer. Sunshine Biopharma’s Adva-27a is also a podophyllotoxin derivative and topoisomerase II inhibitor.

Multi-drug resistance remains a key barrier to cancer treatment

Despite their potential to kill cells, some of the more aggressive cancers may eventually become resistant to chemotherapy and both. They do this mainly by amplifying certain genes to trigger faster cell proliferation and eventually outperform what even the highest doses of these drugs can handle.

Various risk factors can lead to cancer becoming multi-resistant. Some, such as pancreatic cancer or certain types of breast cancer, are resistant from the start and never respond to chemotherapy. Others may develop resistance later.

When this happens, doctors have little access to cancer treatment. Their greatest hope is the use of combination therapy, alternation of different drugs and therapies in the hope of preventing or delaying resistance.

Because it doesn’t really overcome or reverse resistance, it’s not a bulletproof approach, and resistance can and do develop even when patients undergo combination therapy. As a result, multidrug resistance results in more than 90% of deaths in patients receiving chemotherapy.

Adva-27a could provide doctors with a multi-drug-resistant cancer weapon

Adva-27a is Sunshine’s response to the reduction of multidrug resistance faced by etoposide and teniposide. It is said to be a more potent topoisomerase II inhibitor that is ideally able to kill cancer cells that other compounds cannot.

Preclinical studies to date by Sunshine show early indications that Adva-27a may be able to fill a gap left by other topoisomerase inhibitors, providing doctors with a way to treat cancers that no longer respond to chemotherapy. A recent study also stated that “new mRNA molecules are easily adaptable for delivery to patients using mRNA vaccine technology. The company recently announced that it has filed a patent application in connection with these results.

The researchers found that the new compound was effective in killing multidrug-resistant cancer cells in pancreatic cancer, breast cancer, small cell lung cancer and uterine cancer. The compound boasted better metabolic stability and better cancer cell killing activity in multidrug resistant cancers compared to etoposide.

The company is now producing 5 kilograms (11 pounds) of the compound in preparation for another new drug research (IND). With data from this upcoming IND study, beyond its current preclinical results, Sunshine hopes to accelerate a drug candidate for clinical trials at McGill University Jewish General Hospital.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended as investment advice.

Image courtesy of Pixabay



Source link

Leave a Comment

Your email address will not be published.